SG11202104460UA - Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors - Google Patents
Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitorsInfo
- Publication number
- SG11202104460UA SG11202104460UA SG11202104460UA SG11202104460UA SG11202104460UA SG 11202104460U A SG11202104460U A SG 11202104460UA SG 11202104460U A SG11202104460U A SG 11202104460UA SG 11202104460U A SG11202104460U A SG 11202104460UA SG 11202104460U A SG11202104460U A SG 11202104460UA
- Authority
- SG
- Singapore
- Prior art keywords
- compounds
- methods
- pharmaceutical compositions
- kinase inhibitors
- atr kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752873P | 2018-10-30 | 2018-10-30 | |
| US201962877177P | 2019-07-22 | 2019-07-22 | |
| PCT/CA2019/051539 WO2020087170A1 (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202104460UA true SG11202104460UA (en) | 2021-05-28 |
Family
ID=70461742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202104460UA SG11202104460UA (en) | 2018-10-30 | 2019-10-30 | Compounds, pharmaceutical compositions, and methods of preparing compounds and of their use as atr kinase inhibitors |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20210277002A1 (de) |
| EP (1) | EP3873905A4 (de) |
| JP (1) | JP2022510501A (de) |
| KR (1) | KR20210097124A (de) |
| CN (1) | CN113454080A (de) |
| AU (1) | AU2019373416A1 (de) |
| BR (1) | BR112021008336A2 (de) |
| CA (1) | CA3118218A1 (de) |
| CR (1) | CR20210281A (de) |
| EC (1) | ECSP21038390A (de) |
| IL (1) | IL282801A (de) |
| MA (1) | MA54091A (de) |
| MX (1) | MX2021005012A (de) |
| PH (1) | PH12021550992A1 (de) |
| SG (1) | SG11202104460UA (de) |
| WO (1) | WO2020087170A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2020317381A1 (en) * | 2019-07-22 | 2022-02-10 | Repare Therapeutics Inc. | Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors |
| CA3164203A1 (en) * | 2019-12-11 | 2021-06-17 | Repare Therapeutics Inc. | Use of atr inhibitors in combination with parp inhibitors |
| WO2022002243A1 (zh) * | 2020-07-02 | 2022-01-06 | 江苏恒瑞医药股份有限公司 | 咪唑并嘧啶类衍生物、其制备方法及其在医药上的应用 |
| CN116507337A (zh) * | 2020-08-07 | 2023-07-28 | 上海德琪医药科技有限公司 | Atr抑制剂及其用途 |
| CN116234551A (zh) * | 2020-09-27 | 2023-06-06 | 南京明德新药研发有限公司 | 一类1,7-萘啶类化合物及其应用 |
| MX2023012696A (es) * | 2021-04-28 | 2024-01-22 | Repare Therapeutics Inc | Metodos de tratamiento de canceres con una mutacion de sobreexpresion genica o perdida de funcion bialelica. |
| IL309388A (en) * | 2021-06-16 | 2024-02-01 | Repare Therapeutics Inc | Combining ATR inhibitors and PARP inhibitors for cancer treatment |
| CN118043325A (zh) | 2021-07-27 | 2024-05-14 | 励缔(杭州)医药科技有限公司 | 8-氧-3-氮杂二环[3.2.1]辛烷类化合物或其盐及其制备方法和用途 |
| AU2022325376A1 (en) * | 2021-08-11 | 2024-02-22 | Wigen Biomedicine Technology (shanghai) Co., Ltd. | Naphthyridine derivative as atr inhibitor and method for preparing same |
| CN116262749A (zh) * | 2021-12-15 | 2023-06-16 | 上海翊石医药科技有限公司 | 一类芳杂环取代的化合物及其制备方法和用途 |
| WO2023193114A1 (en) * | 2022-04-07 | 2023-10-12 | Repare Therapeutics Inc. | Methods of using atr inhibitors |
| WO2024123932A1 (en) | 2022-12-07 | 2024-06-13 | F. Hoffmann-La Roche Ag | Crystalline salt form of atr inhibitor |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040048866A1 (en) * | 2002-03-08 | 2004-03-11 | Teodozyj Kolasa | Indazole derivatives that are activators of soluble guanylate cyclase |
| RS61281B1 (sr) * | 2009-12-31 | 2021-02-26 | Hutchison Medipharma Ltd | Sintetički intermedijer koristan u pripremi triazolopiridinskih c-met inhibitora |
| US9073924B2 (en) * | 2011-09-13 | 2015-07-07 | Glaxosmithkline Llc | Azaindazoles |
| WO2013067302A1 (en) * | 2011-11-04 | 2013-05-10 | Glaxosmithkline Intellectual Property (No. 2) Limited | Method of treatment |
| US8906910B2 (en) * | 2011-12-20 | 2014-12-09 | Glaxosmithkline Llc | Imidazopyridine derivatives as PI3 kinase |
| TWI700283B (zh) * | 2014-08-04 | 2020-08-01 | 德商拜耳製藥公司 | ２-(嗎啉-４-基)-１,７-萘啶 |
| MA41988B1 (fr) * | 2015-04-29 | 2021-03-31 | Janssen Pharmaceutica Nv | Azabenzimidazoles et leur utilisation comme modulateurs du recepteur ampa |
| CA3011189C (en) * | 2016-01-14 | 2024-02-20 | Bayer Pharma Aktiengesellschaft | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines |
-
2019
- 2019-10-30 CA CA3118218A patent/CA3118218A1/en active Pending
- 2019-10-30 JP JP2021547609A patent/JP2022510501A/ja active Pending
- 2019-10-30 AU AU2019373416A patent/AU2019373416A1/en active Pending
- 2019-10-30 BR BR112021008336-7A patent/BR112021008336A2/pt unknown
- 2019-10-30 EP EP19878747.5A patent/EP3873905A4/de active Pending
- 2019-10-30 CR CR20210281A patent/CR20210281A/es unknown
- 2019-10-30 MX MX2021005012A patent/MX2021005012A/es unknown
- 2019-10-30 KR KR1020217016338A patent/KR20210097124A/ko unknown
- 2019-10-30 CN CN201980087223.7A patent/CN113454080A/zh active Pending
- 2019-10-30 SG SG11202104460UA patent/SG11202104460UA/en unknown
- 2019-10-30 WO PCT/CA2019/051539 patent/WO2020087170A1/en unknown
- 2019-10-30 MA MA054091A patent/MA54091A/fr unknown
-
2021
- 2021-04-29 IL IL282801A patent/IL282801A/en unknown
- 2021-04-30 PH PH12021550992A patent/PH12021550992A1/en unknown
- 2021-04-30 US US17/245,574 patent/US20210277002A1/en active Pending
- 2021-05-28 EC ECSENADI202138390A patent/ECSP21038390A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN113454080A (zh) | 2021-09-28 |
| CR20210281A (es) | 2021-10-25 |
| IL282801A (en) | 2021-06-30 |
| EP3873905A4 (de) | 2022-08-17 |
| MX2021005012A (es) | 2021-07-21 |
| EP3873905A1 (de) | 2021-09-08 |
| KR20210097124A (ko) | 2021-08-06 |
| AU2019373416A1 (en) | 2021-06-10 |
| WO2020087170A1 (en) | 2020-05-07 |
| ECSP21038390A (es) | 2021-08-31 |
| MA54091A (fr) | 2021-09-15 |
| BR112021008336A2 (pt) | 2021-08-03 |
| CA3118218A1 (en) | 2020-05-07 |
| US20210277002A1 (en) | 2021-09-09 |
| JP2022510501A (ja) | 2022-01-26 |
| PH12021550992A1 (en) | 2021-10-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282801A (en) | Compounds, pharmaceutical compounds, and methods of making compounds and using them as ATR kinase inhibitors | |
| HK1253537A1 (zh) | 吡咯並嘧啶激酶抑制劑的藥用鹽、物理形態和組合物及其製備方法 | |
| PH12018501151A1 (en) | Tank-binding kinase inhibitor compounds | |
| EP3389663A4 (de) | Pyrrolopyrimidinverbindungen, verwendung als hemmer der lrrk2-kinase und verfahren zur herstellung davon | |
| EP3672973A4 (de) | Heterocyclische verbindungen als kinase-inhibitoren, zusammensetzungen damit und verfahren zur verwendung davon | |
| EP3310339A4 (de) | Ophthalmische formulierungen von tyrosin-kinase-inhibitoren, verfahren zur verwendung davon und herstellungsverfahren dafür | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| IL250447A0 (en) | Stable and soluble formulations of receptor tyrosine kinase inhibitors and methods for their preparation | |
| HK1258996A1 (zh) | 新型fyn激酶抑制劑的方法、組合物以及用途 | |
| ZA201901717B (en) | Polymorphic form of kinase inhibitor compound, pharmaceutical composition containing same, and preparation method therefor and use thereof | |
| IL289763A (en) | Compounds, pharmaceutical compounds and methods for preparing compounds and their use | |
| HK1245678A1 (zh) | 使用酪氨酸激酶抑制劑的組合物和方法 | |
| IL264593A (en) | Medicinal preparations containing akt protein kinase inhibitors | |
| IL283599A (en) | Tyrosine kinase inhibitors, preparations and methods | |
| IL252901A0 (en) | Pharmaceutical preparations of tropomyosin-related kinase (trk) inhibitors | |
| HK1226065A1 (zh) | 連接物關聯激酶1的抑制劑、包含其的組合物、及其使用方法 | |
| IL267829B (en) | History of new amino-imidazopyridines as Janus kinase inhibitors and their pharmaceutical use | |
| EP3717475A4 (de) | Kinaseinhibitorverbindungen und zusammensetzungen und verfahren zur verwendung | |
| ZA202103858B (en) | Tyrosine kinase inhibitors, compositions and methods there of | |
| GB201705201D0 (en) | Novel compounds and their use as kinase inhibitors | |
| EP3681492A4 (de) | Verbindungen, pharmazeutische zusammensetzungen und verwendung davon als inhibitoren der ran-gtpase | |
| GB201609580D0 (en) | Novel compounds and their use as kinase inhibitors |